Advertisement
Canada markets open in 7 hours 38 minutes

  • S&P/TSX

    21,885.38
    +11.66 (+0.05%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CAD/USD

    0.7328
    +0.0005 (+0.07%)
     

  • CRUDE OIL

    83.94
    +0.37 (+0.44%)
     

  • Bitcoin CAD

    87,896.01
    +162.92 (+0.19%)
     

  • CMC Crypto 200

    1,389.02
    +6.45 (+0.47%)
     

  • GOLD FUTURES

    2,346.90
    +4.40 (+0.19%)
     

  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     

  • 10-Yr Bond

    4.7060
    -4.6520 (-49.71%)
     

  • NASDAQ futures

    17,764.50
    +197.00 (+1.12%)
     

  • VOLATILITY

    15.37
    -0.60 (-3.76%)
     

  • FTSE

    8,078.86
    +38.48 (+0.48%)
     

  • NIKKEI 225

    38,005.71
    +377.23 (+1.00%)
     

  • CAD/EUR

    0.6829
    +0.0008 (+0.12%)
     

Will Oncothyreon (ONTY) Crush Estimates at Its Next Earnings Report?

Zacks Equity Research

Looking for a stock that might be in a good position to beat earnings at its next report? Consider Oncothyreon Inc (ONTY), a firm in the Medical-biomed/Gene industry, which could be a great candidate for another beat.

This company has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. In fact, in these reports, ONTY has beaten estimates by at least 15% in both cases, suggesting it has a nice short-term history of crushing expectations.

Earnings in Focus

Two quarters ago, ONTY expected to deliver a loss of 12 cents per share, while it actually produced loss of 10 cents per share, a beat of 16.7%. Meanwhile, for the most recent quarter, the company looked to deliver loss of 13 cents per share, when it actually saw loss of 7 cents per share instead, representing a 46.1% positive surprise.

Thanks in part to this history, recent estimates have been moving higher for Oncothyreon. In fact, the Earnings ESP for ONTY is positive, which is a great sign of a coming beat.

After all, the Zacks Earnings ESP compares the most accurate estimate to the broad consensus, looking to find stocks that have seen big revisions as of late, suggesting that analysts have recently become more bullish on the company’s earnings prospects. This is the case for ONTY, as the firm currently has a Zacks Earnings ESP of 9.09%, so another beat could be around the corner.

This is particularly true when you consider that ONTY has a great Zacks Rank #2 (Buy) which can be a harbinger of outperformance and a signal for a strong earnings profile.
And when you add this solid Zacks Rank to a positive Earnings ESP, a positive earnings surprise happens nearly 70% of the time, so it seems pretty likely that ONTY could see another beat at its next report, especially if recent trends are any guide.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>





ONCOTHYREON (ONTY): Free Stock Analysis Report


Zacks Investment Research